This study investigated whether the PROSTest, a molecular assay analyzing prostate cancer-specific transcripts, could predict treatment response or prognosis in mCRPC patients receiving docetaxel, compared to changes in prostate-specific antigen (PSA) levels. This evidence concerns the gene KLK3 and Familial prostate cancer.